sanofi nasdaq - Search News

Sanofi (SNY) Q4 2024 Earnings Call Transcript

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the usual forward-looking statements.

Wall Street Journal · 13h

Sanofi Expects Strong Earnings Growth This Year, Plans $5.2 Billion Buyback

The pharmaceutical company forecasts business earnings per share growth at a low double-digit percentage and plans to launch a $5.2 billion share buyback.

Houston Chronicle · 14h

Sanofi: Q4 Earnings Snapshot

The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of 71 cents per share. The drugmaker posted revenue of $11.27 billion in the period, which also fell short of Street forecasts.

Hosted on MSN · 15h

Sanofi forecasts stronger profit growth, announces €5 billion stock buyback

Sanofi (NASDAQ:SNY) announced on Thursday that it plans to repurchase €5 billion ($5.21 billion) worth of shares this year and may take a more active approach to acquisitions in the near term. The move comes as the company prepares to sell a significant stake in its consumer health business.

2hon MSN

Sanofi upgraded to hold by Deutsche Bank

Deutsche Bank has upgraded Sanofi (NASDAQ:SNY) to hold from sell, citing the company's Q4 earnings report. The investment ...

Sanofi (NASDAQ:SNY) Shares Sold by Geneos Wealth Management Inc.

Geneos Wealth Management Inc. decreased its position in Sanofi (NASDAQ:SNY – Free Report) by 2.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 10,223 shares of the company’s stock ...

Sanofi’s Promising Future: Buy Rating Backed by Strategic Moves and Strong Pipeline

Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst David Risinger from ...

8hon MSN

Earnings call transcript: Sanofi Q4 2024 sees strong growth in sales, EPS

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales rose ...

Time To Be Bullish On Sanofi Ahead Of Its Earnings

Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...

Traders Buy Large Volume of Put Options on Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNY – Get Free Report) was the target of unusually large options trading on Monday. Traders acquired 2,013 put options on the company. This is an increase of approximately 68% compared ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results